1,227 results on '"Verbeek, Marcel M."'
Search Results
2. Temporal Ordering of Biomarkers in Dutch-Type Hereditary Cerebral Amyloid Angiopathy
3. Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy
4. An emerging biomarker for dopaminergic cell loss
5. Correction: Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid angiopathy
6. Altered brain expression and cerebrospinal fluid levels of TIMP4 in cerebral amyloid angiopathy
7. Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy
8. The relation of a cerebrospinal fluid profile associated with Alzheimer’s disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy
9. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy
10. Neuropsychiatric symptoms with focus on apathy and irritability in sporadic and hereditary cerebral amyloid angiopathy
11. Cerebrospinal fluid shotgun proteomics identifies distinct proteomic patterns in cerebral amyloid angiopathy rodent models and human patients
12. An attenuated, adult case of AADC deficiency demonstrated by protein characterization
13. Divergent Associations of Slow‐Wave Sleep versus Rapid Eye Movement Sleep with Plasma Amyloid‐Beta
14. Factors associated with mortality in early stages of parkinsonism
15. Mechanisms of peripheral levodopa resistance in Parkinson’s disease
16. Profiling amyloid‐β peptides as biomarkers for cerebral amyloid angiopathy.
17. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia
18. The novel P330L pathogenic variant of aromatic amino acid decarboxylase maps on the catalytic flexible loop underlying its crucial role
19. Translational validation of shotgun proteomics findings in cerebrospinal fluid of sporadic cerebral amyloid angiopathy patients
20. Shotgun proteomics for the discovery of protein biomarkers for cerebral amyloid angiopathy
21. Full complement activation is associated with capillary cerebral amyloid angiopathy in Alzheimer’s disease.
22. Profiling amyloid‐β peptides as diagnostic biomarkers for cerebral amyloid angiopathy
23. Identification of CSF biomarkers for cerebral amyloid angiopathy using a targeted proteomics approach
24. Tissue inhibitor of matrix metalloproteinases 4: a novel marker associated with CAA
25. Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective.
26. Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase
27. Correction to: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy
28. Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy
29. Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach
30. MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy
31. Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy
32. Linking APOE-ε4, blood-brain barrier dysfunction, and inflammation to Alzheimer's pathology
33. Reinforcement learning in Parkinson’s disease is not associated with inflammatory tone
34. Reduced Influence of apoE on Aβ43 Aggregation and Reduced Vascular Aβ43 Toxicity as Compared with Aβ40 and Aβ42
35. Valuing biomarker diagnostics for dementia care: enhancing the reflection of patients, their care-givers and members of the wider public
36. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study
37. Autoimmune Encephalitis Resembling Dementia Syndromes
38. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review
39. Activation of TNF Receptor 2 Improves Synaptic Plasticity and Enhances Amyloid-β Clearance in an Alzheimer’s Disease Mouse Model with Humanized TNF Receptor 2
40. Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective
41. Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy
42. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease
43. Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study
44. Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson’s disease
45. Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls
46. Reply to: Letter for: Decreased cerebrospinal fluid A β 38, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy
47. Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
48. Reader response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease
49. Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage
50. Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.